Ernexa Therapeutics Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities
Ernexa Therapeutics Inc. (ERNA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities of -$185.00 thousand as of 2011-12-31, per its 10-K filed 2013-03-29.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities · last filed 2013-03-29
- 2011-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities -$185.00K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities |
|---|---|
| 2011-12-31 | -$185.00K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |